1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Five-Year Data Consolidate Cosentyx Benefits

 
• By Kevin Grogan

Cosentyx sales are growing at an impressive rate – up 37% in Q3 – and strong five-year safety and efficacy data in psoriatic arthritis and ankylosing spondylitis is likely to drive that growth even higher.

Building blocks
Cosentyx backed by five years of strong data in AS and PsA • Source: Shutterstock

Novartis AG has been highlighting yet more long-term data on Cosentyx (secukinumab) which emphasizes the efficacy of the blockbuster in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), as well as psoriasis.

Data presented at the American College of Rheumatology and the Association of Rheumatology Professionals (ACR/ARHP) meeting in Chicago on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.